Date:4/20/2009

n, and our reliance upon, third party suppliers, manufacturers, distributors and alliance partners; our ability to attract and retain qualified personnel; our ability to effectively and efficiently manage the planned growth of our operations; our ability to obtain, and the timing of, necessary regulatory approvals; our ability to profitably sell our products at prices that would be acceptable to third-party reimbursement programs; competition including competition from others with significantly more resources; market acceptance of our products and the size of our markets; changes in business strategy or development plans; changes in, or the failure to comply with, governmental regulations; fluctuations in interest rates and foreign exchange rates; seasonality including government budget cycles; general economic and business conditions where we operate; and other factors referenced in our annual report, our Annual Information Form (AIF) (Form 20-F in the U.S.) and other filings with Canadian and United States securities regulatory authorities.

Given these uncertainties, assumptions and risks, readers are cautioned not to place undue reliance on such forward-looking statements or information. We disclaim any obligation to update, or to publicly announce any revisions to, any such statements or information to reflect future results, events or developments, except as required by law.

'/>"/>

SOURCE Response Biomedical Corp. Copyright©2009 PR Newswire. All rights reserved

0 GOOD

Page: 1 2 3 4
Related medicine news :

1. Nationwide Foundation Donates $1.7 Million to American Red Cross for Disaster Preparedness and Response and Increased Blood Collections
2. Groundbreaking First Response Spray Now Available in Europe
3. Cigarette smoke may alter immune response in COPD exacerbations
4. Video: New First Response(R) Fertility Test Helps Women Answer the Question: Am I Able to Get Pregnant?
5. Stanford Study on CyberKnife Radiosurgery for Prostate Cancer Demonstrates 100 Percent PSA Response at 33 months
6. Response to Association Between Hospital-Reported Leapfrog Safe Practices Scores and Inpatient Mortality, Journal of the American Medical Association (JAMA); April 1, 2009
7. Response Biomedical Corporation Reports 2008 Financial Results
8. Tray-Pak Direct Mailer Garners 21% Response, Design Award
9. 2-day results predict ultimate response to therapy in chronic hepatitis C
10. In Hepatitis C Virus Treatment, Interviewed Experts Indicate That Telaprevir- and Boceprevir-Based Regimens Have Advantages Over Pegasys/Ribavirin in Sustained Virologic Response
11. Warner Chilcott Announces Receipt of FDA Response to Citizen Petition